Usefulness of the octreotide test in Japanese patients for predicting the presence/absence of somatostatin receptor 2 expression in insulinomas

What Was Tested

This clinical trial paper looks at Octreotide and Somatostatin.

The researchers investigated the relationship between the results of the octreotide test and somatostatin receptor (SSTR) 2 expression in insulinoma patients, to evaluate the usefulness of this test for predicting SSTR2 expression in insulinomas in Japanese patients.

Why It Was Studied

All patients underwent the octreotide test before the surgery carried out to resect the tumor, and histopathological examination of the resected tumor was performed by a single experienced pathologist.

Insulinoma was clinically diagnosed and surgically resected in all six patients.

Who Took Part

The study group was 2 patients.

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

Five females and one male were included in the study.

SSTR2 expression was evaluated by the SSTR2 immunohistochemistry scoring system.

What Was Measured

All patients underwent the octreotide test before the surgery carried out to resect the tumor, and histopathological examination of the resected tumor was performed by a single experienced pathologist.

In the octreotide test, suppression of insulin secretion was sufficient after loading in patients 1-4 and 6.

The subject headings attached to it are Diagnostic Techniques, Endocrine, Gene Expression Regulation, Neoplastic, Glucose Tolerance Test, Insulinoma, Japan, Octreotide and Pancreatic Neoplasms.

What This Means in Plain Language

This is a clinical trial of Octreotide and Somatostatin in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2016 (Endocrine journal), a journal based in Japan.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.